-
Thematic Analysis
Precision and Personalized Medicine in Pharma – Thematic Intelligence
Precision and Personalized Medicine in Pharma Thematic Report Overview Precision and personalized medicine have already begun to reshape disease treatment paradigms and the provision of healthcare. Improved patient outcomes, increased quality of life, reduced financial and time expenditure of disease management with curative therapies, and a shift from reactive to proactive care are all driving investment in R&D in this space. The precision and personalized medicine in pharma thematic intelligence report provides a focused chapter on the key healthcare, technology,...
-
Company Profile
Parexel International Corp – Company Profile
Parexel International Corp (Parexel), a subsidiary of Pamplona Capital Management LLP is a biopharmaceutical outsourcing service company. It provides services for managing the biopharmaceutical product lifecycle and for the development and commercialization of new medical therapies. It offers an array of services including clinical trials management, observational studies and patient/disease registries, data management, biostatistical analysis, epidemiology, health economics/outcomes research, pharmacovigilance, medical communications, clinical pharmacology, patient recruitment, clinical supply and drug logistics, post-marketing surveillance, regulatory and product development, and commercialization consulting...
Add to Basket -
Company Profile
Oxurion NV – Company Profile
Oxurion NV (Oxurion), formerly ThromboGenics NV, is a biotechnology company, which develops and commercializes ophthalmic and cancer therapeutics. The company’s ocriplasmin, a recombinant derivative of the plasmin protein, is commercialized as Jetrea in the US to treat symptomatic vitreomacular adhesion (VMA) and vitreomacular traction (VMT). Oxurion’s product pipeline includes THR-687, a pan-RGD integrin antagonist being developed for the treatment of diabetic retinopathy, and THR-149, a plasma kallikrein inhibitor, for the treatment of diabetic macular edema (DME). It has commercialization agreements...
Add to Basket -
Thematic Analysis
Social Responsibility Trends in Healthcare – Thematic Intelligence
This report analyzes the impact of social responsibility pressures on the Healthcare sector. Who Should Buy Senior executives and ESG executives in Healthcare industry.
-
Thematic Analysis
Corporate Governance Trends in Healthcare – Thematic Intelligence
This report analyzes the impact of corporate governance pressures on the Healthcare sector. Who Should Buy Senior executives and ESG executives in Healthcare industry.
-
Thematic Analysis
Environmental Trends in Healthcare – Thematic Intelligence
This report analyzes the impact of environmental pressures on the Healthcare Sector. Who Should Buy Senior executives and ESG executives in Healthcare industry.
-
Thematic Analysis
Clinical Trials Sector Scorecard, Q2 2022 Update – Thematic Research
In Q2 2022, there was increased activity in the virtual care space. Compared to Q1 2022, Novo Nordisk initiated more trials with virtual components and posted more jobs related to virtual care. Daiichi Sankyo and Takeda are planning a study in Japan that will look at the feasibility of using a wearable device to track lifestyle habits. Sanofi announced several social initiatives, including the successful pricing of its first bond linked to improving access to essential medicine, the launch of...
-
Thematic Analysis
Pharmaceutical Drug Development Sector Scorecard, Q2 2022 Update – Thematic Research
The genomics landscape was active in Q2 2022, with scores increasing for several companies. This includes Merck & Co, whose score increased to 4 due to an increase in forecasted sales for several Phase II candidates, including its oncolytic vaccine Cavatak (gebasaxturev), an mRNA vaccine, and its recombinant vector vaccine V-184 for Chikungunya fever. In Regenerative Medicine, AstraZeneca saw an increase in its score due to forecasted global sales for its oligonucleotide AZD-8601 and an increase in posted jobs in...
-
Track & Monitor
Pharmaceutical and Healthcare Sector Mergers, Acquisitions and Investment Trend Annual Review – 2021
The pharmaceutical and healthcare sector mergers, acquisitions, and investment trend report is an essential source of data and trend analysis on partnerships, licensing mergers, and acquisitions (M&As), and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceutical industry in the year 2021. It also portrays detailed comparative data on the number of deals and their value in the last six months, subdivided...
-
Track & Monitor
Partnerships, Licensing, Investments and M&A Deals and Trends for July 2021 in Pharmaceuticals
GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for July 2021 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in July 2021. The report portrays detailed comparative data on the number of deals and their value in the last...